# Bayesian Graphical Models for Biomarker Relationships - Applications to Genomics Data <br> Bayesian Graphical models <br> One graph, two, and two hundred million... <br> 2017 Nonclinical Biostatistics Conference 

Yuan Ji, PhD

June 11, 2017

## Collaborator \& References

Collaborators

NorthShore
UT Austin
Johns Hopkins
U. of Louisville
U. of Chicago

Georgia Tech.

Yitan Zhu (Research Scientist)
Peter Müller (Profs)
Yanxun Xu (Assist. Prof.)
Riten Mitra (Assist. Profs)
Lorenzo Pesce and Computational Institute and IGSB Peng Qiu (Assist. Prof.)

## References

- ONE GRAPH :

Mitra et al. (2013, JASA ); Telesca et al. (2012, JASA )

- DIFFERENTIAL GRAPHS :

Mitra et al. (2015a, Bayesian Analysis ; 2015b)

- TWO MILLION GRAPHS :

Zhu et al. (2014, Nature Methods ); Zhu et al. (2015, JNCI )
Website www.compgenome.org

## ONE GRAPH

(Mitra et al., 2013; Telesca et al., 2013)

## Bayesian Graphical Model - An overview

A class of Bayesian graphical hierarchical models Bayesian paradigm:


## Bayesian Graphical Model - An overview

A class of Bayesian graphical hierarchical models
Bayesian paradigm:

$$
\underbrace{\text { Prior Pathways } G_{0}}_{\text {Graphical prior }}+\underbrace{\text { Data }}_{\text {Likelihood }} \rightarrow \underbrace{\text { Posterior Pathways } G}_{\text {Posterior knowledge }}
$$

Graph is random Allow topology to change (add or remove edges); posterior distribution on different graphs
False discovery control FDR is estimated based on posterior probabilities of graphs and edges
Prior graph Prior knowledge can be incorporated (e.g., consensus network from KEGG, GeneGO, Ingenuity...)

## General structure

Bayesian paradigm:


## General structure

Bayesian paradigm:


Notation:
$\boldsymbol{Y}$ : observed data $y_{g t}$, feature $g$, sample $t$
$\boldsymbol{e}$ : latent indicators $\boldsymbol{e}_{g t} \in\{-1,0,1\}$ for under-, over- and normal expression
$\mathcal{G}:$ Graph - dependence structure (conditional independence)
c: strength of dependence

## Probability Model - 1. Priors on random graph $p(\mathcal{G})$ <br> Let $G=(V, E)$ denote a graph <br> $V$ : set of nodes in the graph (features) <br> $E$ : set of edges between pairs of nodes (edges between features)

## Probability Model - 1. Priors on random graph $p(\mathcal{G})$

Let $G=(V, E)$ denote a graph
$V$ : set of nodes in the graph (features)
$E$ : set of edges between pairs of nodes (edges between features)
Prior on $G$

- Informative prior around $G_{0}$ (consensus protein network): $p(G) \propto \tau^{d\left(G, G_{0}\right)}$
- Can deal with a graph with moderate size (say, 50 nodes)
- Need to have strong prior belief in $G_{0}$
- Example: Cellular protein signaling pathways (Telesca et al., 2012); multi-platform molecular interation map - Zodiac (Zhu et al., 2015)


## Probability Model - 1. Priors on random graph $p(\mathcal{G})$

Let $G=(V, E)$ denote a graph
$V$ : set of nodes in the graph (features)
$E$ : set of edges between pairs of nodes (edges between features)
Prior on $G$

- Informative prior around $G_{0}$ (consensus protein network): $p(G) \propto \tau^{d\left(G, G_{0}\right)}$
- Can deal with a graph with moderate size (say, 50 nodes)
- Need to have strong prior belief in $G_{0}$
- Example: Cellular protein signaling pathways (Telesca et al., 2012); multi-platform molecular interation map - Zodiac (Zhu et al., 2015)
- Vague prior when a prior network is not known: $p(\mathcal{G}) \propto$ const
- Feasible only for graphs with relatively small size (e.g., 15 nodes), see Dobra et al. (2005)
- For histone modifications, little prior knowledge is known about their dependence (Mitra et al. 2013)

Probability Model - 2. Joint prior of features presence given the graph $p(\boldsymbol{e} \mid \boldsymbol{\beta}, \mathcal{G})$
Presence of features: Define $\left\{e_{i t}=1\right\}$ the presence indicator of feature $i$ in location $t$.

Joint distribution of $\boldsymbol{e}$ given $G$ and $\boldsymbol{\beta}$ is defined as $p(\boldsymbol{e} \mid \boldsymbol{\beta}, \mathcal{G})$.

Besag (1974) shows that any joint $p(\boldsymbol{e} \mid \boldsymbol{\beta}, G)$ can be written as

$$
\begin{align*}
& \quad p(\boldsymbol{e} \mid \boldsymbol{\beta}, G)=p(\mathbf{0} \mid \boldsymbol{\beta}, G) \\
& \times \exp \left\{\sum_{i} \beta_{i} e_{i}+\sum_{i<j} \beta_{i j} e_{i} e_{j}+\sum_{i<j<k} \beta_{i j k} e_{i} e_{j} e_{k}+\ldots+\beta_{1 \cdots m} e_{1} \cdots e_{m}\right\}, \tag{1}
\end{align*}
$$

where $\beta_{i_{1} \ldots i_{k}}$ is zero if and only if nodes $i_{1}, \ldots, i_{k}$ do not form a

## Clique

A clique is a set of nodes of which all pairs in the set are connected.


Not a Clique A Clique

## Probability Model -3 . Sampling model $p(\boldsymbol{y} \mid \boldsymbol{e})$

We model $y_{i t}$ as random variable from a mixture distribution of Poisson and Log-normals.

$$
p\left(y_{i t} \mid e_{i t}\right) \propto \begin{cases}\operatorname{Poi}\left(\lambda_{i}\right) /\left(y_{i t}<c_{i}\right) & e_{i t}=0  \tag{2}\\ \pi_{i} \operatorname{LN}\left(\mu_{1 i}, \sigma_{1 i}^{2}\right)+\left(1-\pi_{i}\right) \operatorname{LN}\left(\mu_{2 i}, \sigma_{2 i}^{2}\right) & e_{i t}=1\end{cases}
$$

## Probability Model -3 . Sampling model $p(\boldsymbol{y} \mid \boldsymbol{e})$

We model $y_{i t}$ as random variable from a mixture distribution of Poisson and Log-normals.

$$
p\left(y_{i t} \mid e_{i t}\right) \propto \begin{cases}\operatorname{Poi}\left(\lambda_{i}\right) I\left(y_{i t}<c_{i}\right) & e_{i t}=0  \tag{2}\\ \pi_{i} \operatorname{LN}\left(\mu_{1 i}, \sigma_{1 i}^{2}\right)+\left(1-\pi_{i}\right) \operatorname{LN}\left(\mu_{2 i}, \sigma_{2 i}^{2}\right) & e_{i t}=1\end{cases}
$$

The Poisson/log-normal mixture can be further replaced by introducing a trinary indicator $z_{i t} \in\{-1,0,1\}$ with $p\left(z_{i t} \mid e_{i t}=0\right)=\delta_{-1}\left(z_{i t}\right)$ and $p\left(z_{i t} \mid e_{i t}=1\right)=\pi_{i} \delta_{0}\left(z_{i t}\right)+\left(1-\pi_{i}\right) \delta_{1}\left(z_{i t}\right)$. Then

$$
p\left(y_{i t} \mid e_{i t}\right)= \begin{cases}\operatorname{Poi}\left(\lambda_{i}\right) I\left(y_{i t}<c_{i}\right) & z_{i t}=-1  \tag{3}\\ \operatorname{LN}\left(\mu_{1 i}, \sigma_{1 i}^{2}\right) & z_{i t}=0 \\ \operatorname{LN}\left(\mu_{2 i}, \sigma_{2 i}^{2}\right) & z_{i t}=1\end{cases}
$$

## A fit of the mixture model (ChIP-Seq, Riten et al., 2013)

Histogram of the positive histone counts with density estimate


Figure: Fit of a Poisson/lognormal mixture model to the count data of a feature. The red (peaked) curve is the density of

## Joint Posterior

Let $\boldsymbol{\theta}$ be the parameter vector for the sampling model.
The joint posterior is given by

$$
p(\boldsymbol{Y}, \boldsymbol{z}, \boldsymbol{e}, \boldsymbol{\theta}, G) \propto \underbrace{p(\boldsymbol{Y} \mid \boldsymbol{z}, \boldsymbol{\theta})}_{(3)} p(\boldsymbol{z} \mid \boldsymbol{e}, \boldsymbol{\theta}) \underbrace{p(\boldsymbol{e} \mid \boldsymbol{\beta}, G)}_{(1)} p(\boldsymbol{\theta}) p(\boldsymbol{\beta} \mid G) p(G)
$$

## MCMC and posterior inference

Posterior MCMC simulation proceeds by iterating over the following transition probabilities:

$$
[\boldsymbol{e} \mid G, \boldsymbol{\beta}, \boldsymbol{\theta}, \boldsymbol{Y}],[\mathbf{z} \mid \boldsymbol{e}, \boldsymbol{\theta}, \boldsymbol{Y}],[\boldsymbol{\theta} \mid \boldsymbol{z}, \boldsymbol{Y}],[\boldsymbol{\beta} \mid \boldsymbol{e}, G],[G \mid \boldsymbol{\beta}, \boldsymbol{e}]
$$

## MCMC and posterior inference

Posterior MCMC simulation proceeds by iterating over the following transition probabilities:

$$
[\boldsymbol{e} \mid G, \boldsymbol{\beta}, \boldsymbol{\theta}, \boldsymbol{Y}],[\boldsymbol{z} \mid \boldsymbol{e}, \boldsymbol{\theta}, \boldsymbol{Y}],[\boldsymbol{\theta} \mid \boldsymbol{z}, \boldsymbol{Y}],[\boldsymbol{\beta} \mid \boldsymbol{e}, G],[G \mid \boldsymbol{\beta}, \boldsymbol{e}]
$$

- Updating $\boldsymbol{\beta}$ and $G$ involves evaluating

$$
\begin{equation*}
c(\boldsymbol{\beta}, G)=1 / p(\mathbf{0} \mid \boldsymbol{\beta}, G)=\sum_{\boldsymbol{e}} \exp \left\{\sum_{i} \beta_{i} e_{i}+\sum_{i<j} \beta_{i j}\left(e_{i}-\nu_{i}\right)\left(e_{j}-\nu_{j}\right)\right\} \tag{5}
\end{equation*}
$$

## MCMC and posterior inference

Posterior MCMC simulation proceeds by iterating over the following transition probabilities:

$$
[e \mid G, \beta, \theta, Y],[z \mid e, \theta, Y],[\theta \mid z, Y],[\boldsymbol{\beta} \mid e, G],[G \mid \beta, e]
$$

- Updating $\boldsymbol{\beta}$ and $G$ involves evaluating

$$
\begin{equation*}
c(\boldsymbol{\beta}, G)=1 / p(\mathbf{0} \mid \boldsymbol{\beta}, G)=\sum_{\boldsymbol{e}} \exp \left\{\sum_{i} \beta_{i} e_{i}+\sum_{i<j} \beta_{i j}\left(e_{i}-\nu_{i}\right)\left(e_{j}-\nu_{j}\right)\right\} \tag{5}
\end{equation*}
$$

step 1 Importance sampling to updated $\boldsymbol{\beta}$ (Chen and Shao, 1997; Che, Shao and Ibrahim, 2000)

- Approximate the M-H ratio by importance sampling
step 2 With step 1 and reversible jump, updating $G$.


## CHIP-Seq Example

ChIP-Seq experiment for CD4 T Lymphocytes (Barski et al, 2007; Wang et al., 2008)
HM count data $\left[y_{i t}\right]$ with 50,000 selected locations and 39 types of HMs.
Posterior inference is based on $\hat{P}_{i j}$, the posterior probability of including an edge $\{i, j\}$.

1. Edge selection is based on posterior expected FDR to determine a cutoff $c$

$$
F D R_{c}=\frac{\sum_{i j}\left[\left(1-\hat{P}_{i j}\right) /\left(\hat{P}_{i j}>c\right)\right]}{\sum_{i, j} I\left(\hat{P}_{i j}>c\right)}
$$

so that edges with $\hat{P}_{i j}>c$ are selected.
2. Type of interaction is based on

$$
\operatorname{Pr}\left(\beta_{i j}>0 \mid \beta_{i j} \neq 0, \boldsymbol{y}\right)>0.5
$$

- Yes: positive
- No: negative


## Results - 1: Point Estimate (ChIP-Seq on Histone Modifications)



Posterior inference for the ChIP-Seq data on 17 HMs under a uniform prior $p(G)$. The thickness of the edges indicate the strength of the relationship and is a function of the posterior inclusion probabilities $\hat{P}_{i j}$.

## Results - 2: Variability Estimate


(a) 55

(c) 13

(b) 15

(d) 12

The four most frequent configurations (a through d) of a subgraph consisting of 4 edges. The posterior probabilities (in percent) are given below each subgraph.

# DIFFERENTIAL GRAPHs (> 2 graphs) 

(Mitra, Müller, Ji, 2014a; 2014b)

## Differential Networks of

Assume an informative prior graph $G_{0}$. Inference on two graphs $G^{1}$ and $G^{2}$. Define $\delta_{i j}=\left|G_{i j}^{2}-G_{i j}^{1}\right|$ the differential edge indicator.

$$
\begin{gather*}
G^{1} \mid G_{0} \sim U\left(G_{0}\right) \\
\delta_{i j} \sim \operatorname{Ber}(\pi), i<j \\
\pi \sim \operatorname{Beta}(a, b) . \tag{6}
\end{gather*}
$$

Together $G^{1}$ and $\delta$ implicitly define $G^{2}$ by

$$
G_{i j}^{2}=G_{i j}^{1}\left(1-\delta_{i j}\right)+\left(1-G_{i j}^{1}\right) \delta_{i j}
$$

for all edges $\{i, j\} \in E_{0}$.
We refer to (6) as the differential graph model, and refer to $\pi$ as the global probability of similarity.

## Differential Networks of

Assume an informative prior graph $G_{0}$. Inference on two graphs $G^{1}$ and $G^{2}$. Define $\delta_{i j}=\left|G_{i j}^{2}-G_{i j}^{1}\right|$ the differential edge indicator.

$$
\begin{gather*}
G^{1} \mid G_{0} \sim U\left(G_{0}\right) \\
\delta_{i j} \sim \operatorname{Ber}(\pi), i<j \\
\pi \sim \operatorname{Beta}(a, b) . \tag{6}
\end{gather*}
$$

Together $G^{1}$ and $\delta$ implicitly define $G^{2}$ by

$$
G_{i j}^{2}=G_{i j}^{1}\left(1-\delta_{i j}\right)+\left(1-G_{i j}^{1}\right) \delta_{i j}
$$

for all edges $\{i, j\} \in E_{0}$.
We refer to (6) as the differential graph model, and refer to $\pi$ as the global probability of similarity.

## Differential graphs


(a) Promoters $\left(G^{1}\right)$
(b) Insulators $\left(G^{2}\right)$
(c) Differences $\delta_{i j}=\left|G_{i j}^{1}-G_{i j}^{2}\right|$

Figure: Panels (a) through (c) show posterior estimated networks in two regulatory regions and the posterior estimated differences between them. The solid lines denote the edges present in promoters, but not in insulators while dotted lines represent edges in insulators but not in promoters.

## Extension to $>2$ graphs

- A latent "baseline" graph $G_{0}$;
- Multiple graph model: For graph $G^{k}, k=1,2, \ldots K$,

$$
\begin{gathered}
p\left(G_{i j}^{k}=1 \mid G_{i j}^{0}=1\right)=p_{11}^{k} \quad \text { and } \quad p\left(G_{i j}^{k}=1 \mid G_{i j}^{0}=0\right)=p_{10}^{k} \\
p_{11}^{k}, p_{10}^{k} \sim \operatorname{Beta}\left(a_{1}, b_{1}\right) \\
p\left(G_{i j}^{0}=1\right)=p_{0} ; \quad p_{0} \sim \operatorname{Beta}\left(a_{0}, b_{0}\right)
\end{gathered}
$$

## Extension to Time-Course Proteomics Data

 In Mitra et al. (2014), we consider a time-course data set from a functional proteomics experiment. About 66 proteins from PI3K pathway are measured over 8 time points. We consider a directed graph to estimate the joint dependence structure of these biomarkers.

## 200, 000, 000 GRAPHS <br> (Zhu et al., 2014; 2015)

## Biological goal

Understand genetic interactions in cancer between different genomics features of different genes


## Zodiac: Blueprint



## The Cancer Genome Atlas (TCGA)

- An NCI/NHGRI pilot project (cancergenome.nih.gov), cost about $\$ 1$ billion
- multiple cancer types (>25),
- Multiple -omics (copy number, mRNA, methylation, protein), whole genome, MATCHED samples!

|  | Data | a Levels in TC | $G A$ |
| :---: | :---: | :---: | :---: |
|  | Restricted access |  | Publicly available data |
| Data Type | Level 1 (Raw Data) | Level 2 <br> (Normalized/Processed) | Level 3 (Segmented/Interpreted) |
| $\begin{gathered} \text { Copy Number (CGH } \\ \text { array) } \end{gathered}$ | Raw signals per probe | Normalized signals for copy number alterations of aggregated regions, per probe or probe set | Copy number alterations for aggregated/segmented regions, per sample |
| DNA Methylation | Raw signals per probe | Normalized signals per probe or probe set and allele calls | Methylated sites/genes per sample |
| Exon Expression | Raw signals per probe | Normalized signals per probe set | Expression calls for Exons/ <br> Variants per sample |
| Gene Expression | Raw signals per probe | Normalized signals per probe or probe set | Expression calls for Genes per sample |
| miRNA Expression | Raw signals per probe | Normalized signals per probe or probe set | Expression calls for microRNAs per sample |
| Mutations | NA | Putative mutations | Validated somatic mutations |
| SNP | Raw signals per probe | Normalized signals per probe or probe set | NA |
| Data Size |  |  |  |
| 300 TB |  | 100 GB |  |

## TCGA-Assembler Retrieves Level-3 TCGA data

## TCGA Data Generation and Data Flow

TCGA Centers: Tissue Source Sites (TSS), Biospecimen Core Resources (BCRs), Data Coordinating Center (DCC), Genome Characterization Centers (GCCs), Genome Sequencing Centers (GSCs), Cancer Genomics Hub (CGHub), Genome Data Analysis Centers (GDACs)


## TCGA-Assembler Produces Mega-Data

## Illustration of Combining Multi-modal Data for Integrative Analysis

| Gene expression | Single data table |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Gene Symbol | Platform | Description | $\begin{array}{\|c\|} \hline \text { TCGA- } \\ \text { EI-6506-01 } \\ \hline \end{array}$ | $\begin{array}{c\|} \text { TCGA- } \\ \text { AG-4021-01 } \\ \hline \end{array}$ | $\begin{gathered} \text { TCGA- } \\ \text { AG-4022-01 } \end{gathered}$ | $\begin{array}{\|c\|} \text { TCGA- } \\ \text { AG-3725-01 } \\ \hline \end{array}$ |
|  | AKT1 | GE | 207 | 3109.227 | 4118.632 | 2905.794 | 4008.446 |
|  | AKT1 | PE | Akt-R-V | 1.7805 | 2.0518 | 1.3533 | 2.0111 |
| Protein expre | AKT1 | PE | Akt_pS473-R-V | -1.621 | -3.1844 | -1.6175 | -1.9758 |
| ta fil | AKT1 | PE | Akt_pT308-R-V | -1.3476 | -1.8019 | -1.4822 | -1.2898 |
|  | AKT1 | ME | Overall | 0.720284 | 0.688232 | 0.680361 | 0.662689 |
|  | AKT1 | CN | CHR14- | -0.38 | 0.1423 | -0.1192 | -0.002 |
|  | MIR200C | ME | Overall | 0.189436 | 0.223844 | 0.183301 | 0.116829 |
|  | MIR200C | CN | CHR12+ | 0.0079 | -0.6209 | 0.1662 | -0.0034 |
| miRNA expression | MIR200C | miRExp |  | 16617.82 | 5761.941 | 11792.5 | 26984.18 |
| data file | MIR506 | ME | Overall | 0.771979 | 0.757992 | 0.700243 | 0.671736 |
| $\square$ | MIR506 | CN | CHRX- | 0.0057 | -0.1969 | 0.0017 | 0.0175 |
|  | MIR506 | miRExp |  | 0.277389 | 1.212507 | 0.115049 | 0.06591 |
| - | MTOR | GE | 2475 | 1520.826 | 1496.095 | 1007.077 | 1298.564 |
|  | MTOR | PE | mTOR-R-V | 1.1394 | 1.0414 | 0.82713 | 1.2374 |
| DNA copy numbe | MTOR | PE | mTOR_pS2448-R-C | -1.9719 | -2.3493 | -1.9848 | -1.8108 |
| data file | MTOR | ME | Overall | 0.567012 | 0.585587 | 0.555973 | 0.549771 |
|  | MTOR | CN | CHR1- | -0.1671 | 0.1284 | -0.1071 | -0.0109 |
|  | PACS2 | GE | 23241 | 1141.753 | 1489.029 | 1041.575 | 1304.476 |
|  | PACS2 | ME | Overall | 0.72097 | 0.702261 | 0.708845 | 0.695105 |
|  | PACS2 | CN | CHR14+ | -0.38 | 0.1423 | -0.1192 | -0.002 |
| DNA methylation | TP53 | GE | 7157 | 3783.318 | 2123.094 | 2564.794 | 2444.257 |
| data file | TP53 | ME | Overall | 0.224788 | 0.233938 | 0.223865 | 0.227782 |
|  | TP53 | PE | p53-R-V | -2.059 | -2.8108 | -2.0793 | -2.2214 |
|  | TP53 | CN | CHR17- | 0.0047 | -0.6397 | -0.1182 | -0.4899 |

## Bayesian Graphical Models



## Multi-omics Molecular Interaction Map

## Inference of Intragenic and Intergenic Interactions

- Integrate data from multiple genomic/epigenomic/proteomic assay platforms to infer interaction mechanisms.
- Within and across cancer types
- Intragenic interactions of each gene ( $\sim 20,000$ genes).

Intergenic interactions between each pair of genes ( $\sim 200,000,000$ pairs).


## Big-Data Computation and Visualization



## Massive Parallel Computation

- Analysis of one gene pair takes $\sim 47$ seconds.
- Total required computation time is $\sim 2,459,455 \mathrm{CPU}$ hours.
- Analysis was conducted on Beagle, a super computer with > 17000 CPUs in University of Chicago and Argonne National Laboratory.
- Size of analysis results (~800 GB)
- 19,411 intragenic interaction networks
- ~200 million intergenic interaction networks


## Overlap with Existing Databases of Genomic Regulations

KEGG pathways used for validation of inferred interactions

| Cancers Overview | Pathways in cancer <br> Transcriptional misregulation in cancer <br> Proteoglycans in cancer |
| :---: | :---: |
|  | MAPK signaling pathway |
| PI3K-Akt signaling pathway |  |
| Notch signaling pathway |  |
| mTOR signaling pathway |  |
| Wnt signaling pathway |  |
| Signal Transduction | TGF-beta signaling pathway |
|  | ErbB signaling pathway |
|  | VEGF signaling pathway |
|  | Jak-STAT signaling pathway |
|  | NF-kappa B signaling pathway |

## Overlaps between KEGG and Zodiac

| KEGG Relationship | Enrichment | Fold |
| :---: | :---: | :---: |
| (Corresponding Zodiac relationship) | 2.38 | Enrichment <br> P-value |
| Gene Expression Activation <br> (Positive PE-GE or GE-GE) | 14.17 | $2.92 \mathrm{E}-18$ |
| Protein Phosphorylation <br> (Positive PE-PE(phos) or GE-PE(phos)) <br> Multi-unit Protein and Protein Complex <br> (Positive GE-GE or PE-PE) | 3.10 | 1.29 E -312 |

## Results-1: Intra-genic transcription regulation

| A-i Intragenic interactions within a gene | A-iii Top 10 genes having strongest, significant (Bayesian FDR <= 0.01) positive GE-GE interactions with transcription factor gene EZH2 |  |  |  |
| :---: | :---: | :---: | :---: | :---: |
|  | Gene Symbol | Mean of Strength Coefficient | Gene Symbol | Mean of Strength Coefficient |
|  | HIST1H2BH | 5.92 | SKP2 | 0.49 |
| A-ii Intragenic and intergenic interactions in a pair of genes | EFTY1 | 14.65 | TBC1D3 | 10.49 |
|  | KDM3A | 11.16 | SCLT1 | 10.46 |
|  | MTIF2 | 10.93 | NEK2 | 10.31 |
|  | NEURL | 10.71 | FASTKD1 | 10.21 |
|  | A. Illustration of statistical inference on intragenic and intergenic interaction networks |  |  |  |




Intragenic edges Intergenic edges
C. Numbers of significant edges inferred by analyses

## Results-2: Entire Pathway



## A. Signaling cascade in KEGG prostate cancer pathway


B. Posterior network inferred by BGM analysis

## Results-3: Predictive markers for anti-PD-1 immune treatment

Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade

Dung T. Le ${ }^{1,2,3}$, Jennifer N. Durham ${ }^{1,2,3,^{*}}$, Kellie N. Smith ${ }^{1,3,^{*}}$, Hao Wang ${ }^{3, *^{*}}$, Bjarne R. Bartlett ${ }^{2,4,^{*}}$, Laveet K. Aulakh ${ }^{2,4}$, St...

+ See all authors and affiliations
Science 08 Jun 2017:
eaan6733
DOI: 10.1126/sclence.aan6733

Dung et al.
(2017, Science) discussed predictive biomarkers for anti-PD-1 blockade in treating cancer patients.
B2M is a gene that predicted worse outcome when mutated

## Results-3: Predictive markers for anti-PD-1 immune treatment



The HLA gene family provides instructions for making a group of related proteins known as the human leukocyte antigen (HLA) complex. The HLA complex helps the immune system distinguish the body's own proteins from proteins made by foreign invaders such as viruses and bacteria. Cancer too?

# Zodiac Website: <br> http://www.compgenome.org/zodiac 

Zodiac Blog:<br>http://compgenome.wordpress.com

## Thank you!

## Zodiac 2 - to be continued...

- Patient subgroups defined by different pathway architecture
- Status of pathway activation for individual patient (allowing for precision therapeutic decisions)
- Update existing cancer pathways using TCGA
- Tissue-specific pathways

